CIMZIA® (certolizumab pegol) is indicated for the treatment of moderate to severe rheumatoid arthritis in adult patients when methotrexate (MTX) alone has not been effective. CIMZIA can be used in combination with MTX or as monotherapy in patients intolerant to MTX. It also slows the progression of joint damage and improves physical function.

• Active ingredient: Certolizumab pegol (200 mg).
• Mechanism of action: CIMZIA is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha (TNF-α), a key molecule in the inflammatory process. By inhibiting TNF-α, CIMZIA helps reduce inflammation and autoimmune activity in rheumatoid arthritis.